Genelux (GNLX) Gains from Investment Securities (2023)
Genelux's (GNLX) quarterly Gains from Investment Securities came in at $3.1 million in Q1 2023.
Genelux (GNLX) Gains from Investment Securities (2023) Analysis & Trends
Genelux's Gains from Investment Securities history runs 1 years deep, the most recent figure standing at $3.1 million for Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Genelux | 129.58 Mn | 129.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 3.11 Mn |
| Mar 31, 2023 | 3.11 Mn |